849068-50-4

Usage

Uses

Used in Pharmaceutical Development:
6-CHLORO-1-ETHOXYCARBONYL-7-AZAINDOLE is used as a pharmaceutical agent for its potential therapeutic applications. Its unique molecular structure and functional groups make it a promising candidate for the development of new drugs in the field of medicinal chemistry.
Used in Material Science:
In the field of material science, 6-CHLORO-1-ETHOXYCARBONYL-7-AZAINDOLE is used as a valuable intermediate in the synthesis of other compounds with specific properties and applications. Its unique azaindole core and functional groups contribute to the creation of novel materials with potential uses in various industries.
Used in Chemical Synthesis:
6-CHLORO-1-ETHOXYCARBONYL-7-AZAINDOLE is used as a key intermediate in the synthesis of various chemical compounds. Its presence in the molecular structure allows for the development of new compounds with specific properties, making it a valuable component in chemical synthesis processes.
Used in Research and Development:
In research and development, 6-CHLORO-1-ETHOXYCARBONYL-7-AZAINDOLE is used as a starting material for the exploration of new chemical reactions and the discovery of novel compounds. Its unique properties and reactivity make it an interesting subject for scientific investigation and potential applications in various fields.
Used in Drug Discovery:
6-CHLORO-1-ETHOXYCARBONYL-7-AZAINDOLE is used in drug discovery as a potential lead compound for the development of new therapeutic agents. Its unique molecular structure and functional groups provide opportunities for optimization and modification to enhance its pharmacological properties and therapeutic potential.
Used in Medicinal Chemistry Research:
In medicinal chemistry research, 6-CHLORO-1-ETHOXYCARBONYL-7-AZAINDOLE is used as a valuable tool for studying the structure-activity relationships of indole derivatives. Its unique properties and reactivity contribute to a better understanding of the molecular mechanisms underlying the biological activities of these compounds, paving the way for the development of more effective and targeted therapeutic agents.

Upstream product

• 541-41-3 chloroformic acid ethyl ester 
• 55052-24-9 1H-Pyrrolo[2,3-b]pyridine-7-oxide 
• 79-22-1 methyl chloroformate 
• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 271-63-6 7-Azaindole 

Downstream Products

• 1296200-79-7 N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide 
• 915140-96-4 6-Chloro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid 
• 1296203-11-6 C₁₆H₁₄ClN₃O₂ 
• 1420070-69-4 N-ethyl-N-(5-(trifluoromethyl)-2-(6-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)benzyl)cyclopropanecarboxamide 
• 1420070-56-9 N-[2-(6-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl]-N-ethylcyclopropanecarboxamide 
• 1420532-25-7 N-ethyl-N-(2-(6-ethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl)cyclopropanecarboxamide 
• 1420070-70-7 N-(2-(3-bromo-6-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl)-N-ethylcyclopropanecarboxamide 
• 1420070-57-0 N-[2-(3-bromo-6-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl]-N-ethylcyclopropanecarboxamide 
• 1420532-26-8 ?N-(2-(3-bromo-6-ethyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-5-(trifluoromethyl)benzyl)-N-ethylcyclopropanecarboxamide 
• 1420070-71-8 tert-butyl 2-(1-(2-((N-ethylcyclopropanecarboxamido)methyl)-4-(trifluoromethyl)phenyl)-6-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetate 
• 1420070-58-1 ?tert-butyl {6-cyclopropyl-1-[2-{[(cyclopropylcarbonyl)(ethyl)amino]methyl}-4-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetate 
• 1420071-18-6 C₂₄H₂₁F₆N₃O₃ 
• 1420532-85-9 ?[1-[2-{[(cyclopropylcarbonyl)(ethyl)amino]methyl}-4-(trifluoromethyl)phenyl]-6-(difluoromethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]acetic acid 
• 1420071-14-2 {6-cyclopropyl-1-[2-{[(cyclopropylcarbonyl)(ethyl)amino]methyl}-4-(trifluoromethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetic acid 

Relevant academic research and scientific papers

COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES

The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases

ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS

The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

New CRTh2 antagonists

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I)

Rho kinase (ROCK) inhibitors are potential therapeutic agents to treat disorders such as hypertension, multiple sclerosis, cancers, and glaucoma. Here, we disclose the synthesis, optimization, biological evaluation of potent indole and 7-azaindole based ROCK inhibitors that have high potency on ROCK (IC 50 = 1 nM) with 740-fold selectivity over PKA (47). Moreover, 47 showed very good DMPK properties making it a good candidate for further development. Finally, docking studies with a homology model of ROCK-II were performed to rationalize the binding mode of these compounds and showed the compounds bound in both orientations to take advantage to H-bonds with Lys-121 of ROCK-II.

COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.